Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07081958 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
A Phase 2 study of Obesity or Overweight, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 2
- Development phase
- 340
- Enrollment target
- 20
- Study locations
NCT07081958: Active Phase 2 study of Obesity or Overweight, sponsored by Hoffmann-La Roche.
NCT07081958 is a Phase 2 study of Obesity or Overweight that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 340 participants, below the 809-participant average among 6 other Obesity or Overweight trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07081958, a Phase 2 study of Obesity or Overweight, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 340 participants
- Enrollment target
- 20
- Study locations
Study Summary
This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for chronic weight management in adult participants with obesity or overweight with at least one weight-related comorbidity, but without diabetes mellitus.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RO7795081
Study Locations (20)
North Carolina
- Accellacare of Cary - Cary
- Accellacare - Hickory - Hickory
- Accellacare of Raleigh - Raleigh
- Accellacare of Rocky Mount - Rocky Mount
- Accellacare of Salisbury - Salisbury
California
- Orange County Research Center - Lake Forest
- Prospective Research Innovations Inc. - Rancho Cucamonga
- Asclepes Research Centers - Sherman Oaks
- Encompass Clinical Research - Spring Valley
Florida
- K2 Medical Research-Winter Garden - Clermont
- K2 Medical Research - The Villages - Lady Lake
- K2 Medical Research-Maitland - Maitland
Alabama
- Pinnacle Research Group - Anniston
Connecticut
- Chase Medical Research - Waterbury
District of Columbia
- Emerson Clinical Research Institute LLC - Washington D.C.
Georgia
- Rophe Adult and Pediatric Medicine/SKYCRNG - Union City
Illinois
- Accellacare of Duly Health and Care - Oak Lawn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2025-07-29 |
| Est. Completion | 2026-07-17 |
| Phase | Phase 2 |
What the registry record for NCT07081958 still lists
NCT07081958 is an interventional study that assigns participants to a tested intervention. The registered 340 participants enrollment target is mid-sized for trials with a published cap, below the 809-participant average among 6 other Obesity or Overweight trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Obesity or Overweight appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07081958 names 20 study sites across 11 states, led by North Carolina, California, Florida.
Frequently Asked Questions
What is clinical trial NCT07081958 about?
NCT07081958 is a clinical study titled "A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity". This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for chronic weight management in adult participants with obesity or overweight with at least one weight-related como...
What is the current status of trial NCT07081958?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 340 participants. The study started on 2025-07-29. Estimated completion is 2026-07-17.
What conditions does trial NCT07081958 study?
This clinical trial studies the following conditions: Obesity or Overweight.
What interventions are being tested in trial NCT07081958?
The interventions under investigation include: Placebo (DRUG), RO7795081 (DRUG).
Who is sponsoring clinical trial NCT07081958?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07081958 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity or Overweight
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone
ACTIVE NOT RECRUITING · Phase 2
-
Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions
ACTIVE NOT RECRUITING · Phase 2
-
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight Without Type 2 Diabetes
RECRUITING · Phase 3
-
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
RECRUITING · Phase 3
-
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RECRUITING · Phase 3
-
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
- NCT04545424 · 340 participants · Phase 2
Trial of Therapeutic Hypothermia in Patients With ARDS
- NCT04806958 · 340 participants · NA
The PulsePoint Study
- NCT05323409 · 340 participants · NA
Improving Comprehensive Care of Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI